Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| St. Olavs Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
The aim of this study is to investigate whether the combination of high intensity exercise and time restricted eating before and during pregnancy can reduce the risk of hyperglycaemia during pregnancy.
Women who are planning a pregnancy will be recruited into a parallel groups randomised controlled trial where the intervention will consist of high intensity training and time-restricted eating. The intervention will continue throughout pregnancy. The investigators will assess whether this lifestyle intervention can effect maternal and offspring cardiometabolic health.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| diet + training | Experimental |
| |
| controls | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| time-restricted eating | Behavioral | Participants will be asked to limit the time-window for their daily energy intake to a maximum of 10 hours. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Plasma glucose concentration | Plasma glucose concentration after 2 h oral glucose tolerance testing (75 g glucose) | Gestational week 28 |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma glucose concentration | Plasma glucose concentration after 2 h oral glucose tolerance testing (75 g glucose) | Gestational week 12 |
| HbA1c | Measured in the maternal blood |
| Measure | Description | Time Frame |
|---|---|---|
| Infant gut microbiome | Sequencing of faecal samples | Within one week of birth, after 6 weeks and after 6 months |
| Maternal gut microbiome | Sequencing of faecal samples |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Øystein Risa | Norwegian University of Science and Technology, Fac MH ISB | Study Director |
| Kjell Å Salvesen, md prof | St Olavs Hospital, Dept Obstetrics & Gynecology | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| St Olavs Hospital | Trondheim | Norway |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40925657 | Derived | Sujan MJ, Skarstad HM, Rosvold G, Fougner SL, Follestad T, Salvesen KA, Moholdt T. Time restricted eating and exercise training before and during pregnancy for people with increased risk of gestational diabetes: single centre randomised controlled trial (BEFORE THE BEGINNING). BMJ. 2025 Sep 9;390:e083398. doi: 10.1136/bmj-2024-083398. | |
| 37793933 |
Not provided
Not provided
We will share individual participant data that underlie the results in publications, after deidentification (text, tables, figures, and appendices).
Immediately following publication, with no end date.
Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose, to achieve aims in the approved proposals, or for individual participant data meta-analyses. Proposals should be directed to trine.moholdt@ntnu.no. To gain access, data requestors will need to sign a data access agreement.
Not provided
Not provided
| ID | Term |
|---|---|
| D016640 | Diabetes, Gestational |
| ID | Term |
|---|---|
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D003920 | Diabetes Mellitus |
Not provided
Not provided
| ID | Term |
|---|---|
| D000072696 | High-Intensity Interval Training |
| D059039 | Standard of Care |
| ID | Term |
|---|---|
| D064797 | Physical Conditioning, Human |
| D015444 | Exercise |
| D009043 | Motor Activity |
| D009068 | Movement |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| high intensity exercise | Behavioral | Participants will be encouraged to exercise with high intensity 2-3 times per week |
|
| Standard Care | Other | Standard clinical care |
|
| Baseline, intervention week 8, gestational week 12 and 28 |
| Total cholesterol | Measured in the maternal blood | Baseline, intervention week 8, gestational week 12 and 28 |
| Triglycerides | Measured in the maternal blood | Baseline, intervention week 8, gestational week 12 and 28 |
| High density lipoprotein cholesterol | Measured in the maternal blood | Baseline, intervention week 8, gestational week 12 and 28 |
| Low density lipoprotein cholesterol | Measured in the maternal blood | Baseline, intervention week 8, gestational week 12 and 28 |
| Low density cholesterol | Measured in the maternal blood | Baseline, intervention week 8, gestational week 12 and 28 |
| Glucose | Measured in the blood | Baseline, intervention week 8, gestational week 12 and 28, and in cord blood (delivery) |
| Insulin | Measured in the blood | Baseline, intervention week 8, gestational week 12 and 28, and in cord blood (delivery) |
| Cytokines | Measured in the blood, a panel of 27 cytokines of relevance for inflammatory status (Bio-Plex Pro Human Cytokine 27-plex Assay) | Baseline, intervention week 8, gestational week 12 and 28, and in cord blood (delivery) |
| Adipokines (Adiponectin, Leptin, Ghrelin) | Measured in the maternal blood | Baseline, intervention week 8, gestational week 12 and 28, and in cord blood (delivery) |
| Homocysteine | Measured in the maternal blood | Baseline, intervention week 8, gestational week 12 and 28 |
| Insulin sensitivity | Insulin sensitivity estimated by homeostatic model assessment for insulin resistance (fasting serum insulin concentration (μU/mL) x fasting plasma glucose levels (mmol/L)/22.5) | Baseline, intervention week 8, gestational week 12 and 28, and in cord blood (delivery) |
| Total body mass | Estimated using InBody720 bioimpedance scale. | Baseline, intervention week 8, gestational week 12 and 28 |
| Fat mass | Estimated using InBody720 bioimpedance scale. | Baseline, intervention week 8, gestational week 12 and 28 |
| Muscle mass | Estimated using InBody720 bioimpedance scale. | Baseline, intervention week 8, gestational week 12 and 28 |
| Visceral fat area | Estimated using InBody720 bioimpedance scale. | Baseline, intervention week 8, gestational week 12 and 28 |
| Continuous glucose monitoring | Continuous glucose monitoring using Freestyle Libre (Abbott Diabetes Care), worn for 14 days. | Baseline and 8 weeks intervention |
| Cardiorespiratory fitness | Peak oxygen uptake at a maximum effort exercise test, measured in L/min using Metalyzer. | Baseline and intervention week 8 |
| Blood pressure | Systolic - and diastolic blood pressure (in mmHg) will be measured in the seated position after 15 minutes of rest with an automatic blood pressure device (Welch Allyn, Germany) three times with one minute intervals, in left arm (average of three measurement). | Baseline, intervention week 8, gestational week 12 and 28 |
| Measured physical activity | Measured by SenseWear activity monitor, worn for 7 days. | Baseline |
| Measured physical activity | Measured by Amazfit GTS smartwatch | From baseline and throughout the study period. |
| Diet intake | Online food diary (Lifesum app), 4-day registration (one weekend day and three weekdays= | Every 8 week throughout the trial. |
| Self-reported physical activity | International Physical Activity Questionnaire | Baseline, intervention week 8, gestational week 12 and 28, and every 8 week until delivery or until the participant is excluded from the trial due to not conceiving within 6 months from baseline |
| Sleep | Self-reported: Pittsburgh Sleep Quality Index | Baseline, intervention week 8, gestational week 12 and 28, and every 8 week until delivery or until the participant is excluded from the trial due to not conceiving within 6 months from baseline |
| Chronotype | Self-reported: Hornestberg Morningness Eveningness Questionnaire | Baseline, intervention week 8, gestational week 12 and 28, and every 8 week until delivery or until the participant is excluded from the trial due to not conceiving within 6 months from baseline |
| Psychological general well being | Psychological general well being index (PGWBI) | Baseline, intervention week 8, gestational week 12 and 28, and every 8 week until delivery or until the participant is excluded from the trial due to not conceiving within 6 months from baseline |
| Time to pregnancy | Self-reported | From baseline to pregnancy (up to 36 weeks from enrollment) |
| Psychological well-being | Self-reported: Psychological General Well Being Index | Baseline, intervention week 8, gestational week 12 and 28 and every 8 week throughout the trial. |
| Birth weight (infant) | From hospital record | Delivery |
| Birth length (infant) | From hospital record | Delivery |
| Head circumference of infant | From hospital record | Delivery |
| Apgar score | From hospital record | Delivery, after 1, 5 and 10 minutes |
| ICU admission | From hospital record | Delivery |
| Congenital malformation | From hospital record | Delivery |
| Gestational age at birth | From hospital record | Delivery |
| Length of stay at hospital | From hospital record | Delivery |
| Blood pressure (Infant) | Blood pressure (systolic - and diastolic) | Within 72 hours of birth and after 6 weeks post delivery |
| Cardiac function (Infant) | Ultrasound echocardiography Blood flow and myocardial function will be measured using mechanical wave imaging (MWI). | Within 72 hours of birth and after 6 weeks post delivery |
| Infant total body mass | Estimated using impedance measurements (BioScan tough i8-nano) | Within 72 hours of birth and after 6 weeks post delivery |
| Infant muscle mass | Estimated using impedance measurements (BioScan tough i8-nano) | Within 72 hours of birth and after 6 weeks post delivery |
| Infant fat mass | Estimated using impedance measurements (BioScan tough i8-nano) | Within 72 hours of birth and after 6 weeks post delivery |
| Infant hydration status | Estimated using impedance measurements (BioScan tough i8-nano) | Within 72 hours of birth and after 6 weeks post delivery |
| Infant bone mass | Estimated using impedance measurements (BioScan tough i8-nano) | Within 72 hours of birth and after 6 weeks post delivery |
| After 6 weeks after delivery and after 6 months |
| Breastmilk composition | Breastmilk sampling, for storage (outcomes will be exploratory, not yet specified) | After 6 weeks after delivery and after 6 months |
| Infant total body mass | Estimated using impedance measurements (BioScan tough i8-nano) | At age of 6 months |
| Infant fat mass | Estimated using impedance measurements (BioScan tough i8-nano) | At age of 6 months |
| Infant muscle mass | Estimated using impedance measurements (BioScan tough i8-nano) | At age of 6 months |
| Infant hydration status | Estimated using impedance measurements (BioScan tough i8-nano) | At age of 6 months |
| Infant bone mass | Estimated using impedance measurements (BioScan tough i8-nano) | At age of 6 months |
| Sujan MAJ, Skarstad HMS, Rosvold G, Fougner SL, Nyrnes SA, Iversen AC, Follestad T, Salvesen KA, Moholdt T. Randomised controlled trial of preconception lifestyle intervention on maternal and offspring health in people with increased risk of gestational diabetes: study protocol for the BEFORE THE BEGINNING trial. BMJ Open. 2023 Oct 4;13(10):e073572. doi: 10.1136/bmjopen-2023-073572. |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D009142 |
| Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |
| D019984 | Quality Indicators, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |